$700.22
Value $260B
Thermo Fisher ScientificvsZymeworks
TMO and ZYME stock compared: price, dividend, valuation and results, from SEC filings.
+0.11%
$26.24
Value $1.8B
Thermo Fisher Scientific (TMO) has a market value of $260B and Zymeworks (ZYME) $1.8B. Over the last year, with dividends, TMO moved +19.5% and ZYME +35.5%. The P/E is 36.8 for TMO and 41.8 for ZYME. Dividend yield: TMO 0.26%, ZYME none.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TMO$260B
ZYME$1.8B
TMO is 144 times ZYME
Revenue, 12 months
TMO$47.4B
ZYME$266M
TMO is 178 times ZYME
Net income, 12 months
TMO$7.1B
ZYME$43M
TMO is 163 times ZYME
Operating margin
TMO17.9%
ZYME16.6%
1.3 points apart
ROIC
TMO8.2%
ZYME16.0%
7.8 points apart
P/E
TMO36.8
ZYME41.8
ZYME is 1.1 times TMO
Dividend yield
TMO0.3%
ZYME0.0%
0.3 points apart
5-year return
TMO+11.8%
ZYME+30.2%
18.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TMO+11.8%
ZYME+30.2%
| Period | TMOWith dividends | ZYMEWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +19.5%Price +19.1% | +35.5%Price +35.5% |
| 3 years since November 13, 2023 | +58.8%+16.7% a yearPrice +57.3% | +260.9%+53.4% a yearPrice +260.9% |
| 5 years since November 12, 2021 | +11.8%+2.3% a yearPrice +10.2% | +30.2%+5.4% a yearPrice +30.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
TMOThermo Fisher ScientificZYMEZymeworks
Valuation
TMOZYME| Price | $700.22 | $26.24 |
|---|---|---|
| Market value | $260B | $1.8B |
| Enterprise value (EV) | $295B | $2.0B |
| P/E | 36.8 | 41.8 |
| P/E, 5-year median | 32.7 | – |
| P/B | 4.8 | 7.0 |
| EV/EBIT | 34.9 | 46.4 |
| Free cash flow yield | 2.9% | – |
Results and growth
TMOZYME| Revenue, 12 months | $47.4B | $266M |
|---|---|---|
| Net income, 12 months | $7.1B | $43M |
| Free cash flow, 12 months | $7.6B | -$113M |
| Earnings per share, 12 months | $18.96 | $0.63 |
| Revenue growth, year on year | 3.9% | 38.9% |
| Revenue growth a year, past | +6.7%over 5 years | +22.2%over 5 years |
| EPS growth a year, past | +2.1%over 5 years | – |
Margins and returns on capital
TMOZYME| Gross margin | – | – |
|---|---|---|
| Operating margin | 17.9% | 16.6% |
| Net margin | 14.9% | 16.3% |
| ROIC | 8.2% | 16.0% |
| ROE | 13.4% | 19.9% |
Balance sheet
TMOZYME| Cash | $6.1B | $100M |
|---|---|---|
| Total debt | $41.4B | $392M |
| Net debt / EBITDA | 3.7 | 5.0 |
| Interest cover | 5.5× | – |
Dividends and buybacks
TMOZYME| Dividend yield | 0.3% | – |
|---|---|---|
| Dividend per share, 12 months | $1.84 | – |
| Dividend growth a year, past | +14.3%over 5 years | – |
| Buyback yield | 1.2% | 2.3% |
| Shareholder yield | 1.4% | 2.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Thermo Fisher Scientific or Zymeworks?
By market value, Thermo Fisher Scientific ($260B) is about 143.6 times Zymeworks ($1.8B), at today's prices.
How did TMO and ZYME stock do over the last 5 years?
Since November 12, 2021, TMO's price moved +10.2% and ZYME's +30.2%. With dividends: TMO +11.8% (+2.3% a year), ZYME +30.2% (+5.4% a year). Past returns do not predict future ones.
Which pays the higher dividend, TMO or ZYME?
The dividend yield at today's price is 0.26% for Thermo Fisher Scientific and none for Zymeworks. Over the last twelve months they paid $1.84 and – per share.
What is the P/E of TMO and ZYME?
At today's price, the P/E is 36.8 for TMO and 41.8 for ZYME. It is the share price over the last twelve months' earnings per share.
Which has the higher profit margins, Thermo Fisher Scientific or Zymeworks?
Over the last twelve months, the net margin was 14.9% for Thermo Fisher Scientific and 16.3% for Zymeworks, and the operating margin 17.9% and 16.6%. Revenue was $47.4B and $266M.
Which is the better investment, Thermo Fisher Scientific or Zymeworks?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.